Acadia Healthcare (ACHC) shares plummeted 5.01% in intraday trading, as multiple analysts cut their price targets for the behavioral healthcare provider. The stock's sharp decline comes amid ongoing sector challenges and growing investor caution, reflecting a broader reassessment of the company's valuation and future growth prospects.

Several prominent financial institutions revised their outlook on Acadia Healthcare. UBS adjusted its price target to $28 from $31, while maintaining a Buy rating. Stephens made a more significant cut, lowering its target to $23 from $28. Deutsche Bank also reduced its price target to $33 from $36, though it maintained a Buy rating. These downgrades have likely contributed to the negative sentiment surrounding the stock.

The recent plunge is part of a larger downward trend for Acadia Healthcare. The company's shares have experienced a 30-day decline of 25.6% and a year-to-date drop of over 50%. This persistent weakness has raised questions about the company's ability to navigate the challenging healthcare landscape and maintain growth. Despite some analysts viewing the stock as potentially undervalued, with fair value estimates significantly above the current trading price, investor skepticism appears to be outweighing optimistic projections in the short term.